Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| T cell | 5 studies | 23% ± 2% | |
| CD4-positive, alpha-beta T cell | 4 studies | 39% ± 9% | |
| B cell | 3 studies | 20% ± 2% | |
| plasma cell | 3 studies | 24% ± 3% | |
| erythroblast | 3 studies | 38% ± 23% | |
| erythrocyte | 3 studies | 35% ± 13% | |
| CD8-positive, alpha-beta T cell | 3 studies | 35% ± 7% |
Insufficient scRNA-seq data for expression of CCNA2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 97% | 633.71 | 1401 / 1445 | 100% | 56.51 | 183 / 183 |
| ovary | 97% | 512.83 | 175 / 180 | 97% | 38.23 | 419 / 430 |
| uterus | 96% | 452.02 | 163 / 170 | 97% | 54.02 | 447 / 459 |
| intestine | 96% | 489.57 | 924 / 966 | 98% | 54.51 | 514 / 527 |
| bladder | 95% | 233.62 | 20 / 21 | 93% | 44.07 | 471 / 504 |
| skin | 98% | 1701.14 | 1765 / 1809 | 89% | 28.97 | 421 / 472 |
| stomach | 83% | 298.33 | 298 / 359 | 99% | 52.79 | 282 / 286 |
| lung | 91% | 300.25 | 525 / 578 | 87% | 35.54 | 1003 / 1155 |
| breast | 83% | 161.78 | 380 / 459 | 86% | 29.35 | 956 / 1118 |
| brain | 80% | 201.39 | 2126 / 2642 | 41% | 10.94 | 287 / 705 |
| prostate | 98% | 305.96 | 241 / 245 | 15% | 2.29 | 75 / 502 |
| pancreas | 36% | 52.93 | 118 / 328 | 71% | 14.51 | 126 / 178 |
| adrenal gland | 85% | 187.15 | 220 / 258 | 20% | 5.12 | 45 / 230 |
| thymus | 87% | 198.91 | 565 / 653 | 15% | 8.74 | 93 / 605 |
| liver | 54% | 114.35 | 122 / 226 | 47% | 11.67 | 189 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 60.14 | 29 / 29 |
| spleen | 100% | 616.75 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 72.95 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 13.24 | 1 / 1 |
| kidney | 82% | 190.00 | 73 / 89 | 18% | 2.82 | 161 / 901 |
| adipose | 83% | 201.24 | 1004 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 78% | 157.42 | 1047 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 66% | 1587.45 | 609 / 929 | 0% | 0 | 0 / 0 |
| heart | 55% | 101.68 | 475 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 14% | 1.47 | 11 / 80 |
| muscle | 13% | 18.66 | 107 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0007265 | Biological process | Ras protein signal transduction |
| GO_1990314 | Biological process | cellular response to insulin-like growth factor stimulus |
| GO_0048146 | Biological process | positive regulation of fibroblast proliferation |
| GO_0071373 | Biological process | cellular response to luteinizing hormone stimulus |
| GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
| GO_0071456 | Biological process | cellular response to hypoxia |
| GO_0071392 | Biological process | cellular response to estradiol stimulus |
| GO_0051301 | Biological process | cell division |
| GO_0031100 | Biological process | animal organ regeneration |
| GO_0033762 | Biological process | response to glucagon |
| GO_0043687 | Biological process | post-translational protein modification |
| GO_0071732 | Biological process | cellular response to nitric oxide |
| GO_0006351 | Biological process | DNA-templated transcription |
| GO_0044843 | Biological process | cell cycle G1/S phase transition |
| GO_0071314 | Biological process | cellular response to cocaine |
| GO_0044320 | Biological process | cellular response to leptin stimulus |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0090102 | Biological process | cochlea development |
| GO_2000573 | Biological process | positive regulation of DNA biosynthetic process |
| GO_0044772 | Biological process | mitotic cell cycle phase transition |
| GO_0000086 | Biological process | G2/M transition of mitotic cell cycle |
| GO_0006275 | Biological process | regulation of DNA replication |
| GO_0036120 | Biological process | cellular response to platelet-derived growth factor stimulus |
| GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
| GO_0001939 | Cellular component | female pronucleus |
| GO_0097124 | Cellular component | cyclin A2-CDK2 complex |
| GO_0097122 | Cellular component | cyclin A2-CDK1 complex |
| GO_0005813 | Cellular component | centrosome |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0000307 | Cellular component | cyclin-dependent protein kinase holoenzyme complex |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0001940 | Cellular component | male pronucleus |
| GO_0005634 | Cellular component | nucleus |
| GO_0019904 | Molecular function | protein domain specific binding |
| GO_0019901 | Molecular function | protein kinase binding |
| GO_0016538 | Molecular function | cyclin-dependent protein serine/threonine kinase regulator activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CCNA2 |
| Protein name | Cyclin-A2 (Cyclin-A) (Cyclin A) |
| Synonyms | CCN1 CCNA |
| Description | FUNCTION: Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle. . |
| Accessions | ENST00000274026.10 P20248 |
